Larimar Therapeutics, Inc. (LRMR)
2.24
-0.03
(-1.32%)
USD |
NASDAQ |
Oct 23, 11:03
Larimar Therapeutics Net Income (Quarterly) : -32.78M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -32.78M |
| March 31, 2026 | -29.61M |
| December 31, 2025 | -62.50M |
| September 30, 2025 | -47.71M |
| June 30, 2025 | -26.18M |
| March 31, 2025 | -29.28M |
| December 31, 2024 | -28.82M |
| September 30, 2024 | -15.50M |
| June 30, 2024 | -21.63M |
| March 31, 2024 | -14.65M |
| December 31, 2023 | -12.99M |
| September 30, 2023 | -9.064M |
| June 30, 2023 | -8.366M |
| March 31, 2023 | -6.526M |
| December 31, 2022 | -9.425M |
| September 30, 2022 | -8.32M |
| June 30, 2022 | -8.667M |
| March 31, 2022 | -8.943M |
| December 31, 2021 | -9.134M |
| September 30, 2021 | -16.80M |
| June 30, 2021 | -12.61M |
| March 31, 2021 | -12.09M |
| December 31, 2020 | -14.20M |
| September 30, 2020 | -10.27M |
| June 30, 2020 | -11.33M |
| Date | Value |
|---|---|
| March 31, 2020 | -6.674M |
| December 31, 2019 | -6.075M |
| September 30, 2019 | -8.628M |
| June 30, 2019 | -3.704M |
| March 31, 2019 | -13.11M |
| December 31, 2018 | -14.57M |
| September 30, 2018 | -15.07M |
| June 30, 2018 | -15.78M |
| March 31, 2018 | -15.96M |
| December 31, 2017 | -13.08M |
| September 30, 2017 | -12.58M |
| June 30, 2017 | -13.35M |
| March 31, 2017 | -13.01M |
| December 31, 2016 | -10.44M |
| September 30, 2016 | -14.68M |
| June 30, 2016 | -15.03M |
| March 31, 2016 | -17.74M |
| December 31, 2015 | -23.17M |
| September 30, 2015 | -19.88M |
| June 30, 2015 | -17.76M |
| March 31, 2015 | -13.47M |
| December 31, 2014 | -10.93M |
| September 30, 2014 | -14.69M |
| June 30, 2014 | -6.40M |
| March 31, 2014 | -4.458M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 32.78M |
| EPS Diluted (Quarterly) | -0.3141 |
| Enterprise Value | 85.64M |
| Earnings Yield | -88.53% |
| Normalized Earnings Yield | -88.52 |